All In Biotech

Drug Trial Radar · NCT04285515

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) or Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 488 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

488

Actual

Start

Feb 27, 2020

Primary completion

Nov 30, 2022

Study completion Nov 30, 2022

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Feb 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or major depressive disorder (MDD) who also meet the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) criteria for mixed-features. The study consists of a Screening Period, a Double-blind Treatment Period, and a Safety Follow-up Period.

Conditions

  • Bipolar Depression
  • Major Depressive Disorder

Interventions

  • LumateperoneDrug

    Lumateperone 42mg oral capsule

  • PlacebosDrug

    Placebo oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Day 43

Locations

42 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Garden Grove, California

  • Clinical Site

    Oceanside, California

  • Clinical Site

    Sherman Oaks, California

  • Clinical Site

    Lauderhill, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Orange City, Florida

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Decatur, Georgia

  • Clinical Site

    O'Fallon, Missouri

  • Clinical Site

    Cedarhurst, New York

  • Clinical Site

    New York, New York

  • Clinical Site

    Charlotte, North Carolina

  • Clinical Site

    Bellevue, Washington

  • Clinical Site

    Burgas, Bulgaria

  • Clinical Site

    Kardzhali, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Rousse, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Varna, Bulgaria

  • Clinical Site

    Veliko Tarnovo, Bulgaria

  • Clinical Site

    Vratsa, Bulgaria

  • Clinical Site

    Moscow, Russia

  • Clinical Site

    Saint Petersburg, Russia

  • Clinical Site

    Saint Petersburg, Russia

  • Clinical Site

    Saint Petersburg, Russia

  • Clinical Site

    Saint Petersburg, Russia

  • Clinical Site

    Saint Petersburg, Russia

  • Clinical Site

    Tomsk, Russia

  • Clinical Site

    Yekaterinburg, Russia

  • Clinical Site

    Belgrade, Serbia

  • Clinical Site

    Kovin, Serbia

  • Clinical Site

    Kragujevac, Serbia

  • Clinical Site

    Kyiv, Ukraine

  • Clinical Site

    Lviv, Ukraine

  • Clinical site

    Odesa, Ukraine

  • Clinical Site

    Odesa, Ukraine

  • Clinical Site

    Poltava, Ukraine

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.